The Ultimate Guide To Decentralized Clinical Trials

Sponsors depend on CROs to adapt—biopharmas outsource roughly 50% to CROs, and that percentage continues to grow each year. CROs who quickly adapt to decentralization using proven innovative technology complemented by an unmatched partnership experience gain a competitive edge, and the opportunity to rise above industry challenges. Required in-person monitoring and hospital visits, site closures due to a lack of enrollment and disruption in the clinical supply chain contribute heavily to delays. Add in the constant evolution of the study design during various phases and CROs experience lost revenue and smaller margins. Decentralized trials reduce some of those risk factors. This eBook reviews four critical steps CROs need to consider when looking to leverage DCT technologies in order to adapt business processes to support today’s hybrid and decentralized trials.